Intravenous Single-Dose Toxicity of Redaporfin-Based Photodynamic Therapy in Rodents

International Journal of Molecular Sciences

Luis B. Rocha²  Fปio Schaberle²  Janusz M. Dၛrowski⁴  Sérgio Simཞs⁵  Luis G. Arnaut³  Michael R. Hamblin¹ 

[1] Luzitin SA, S. Martinho do Bispo, Coimbra 3045-016, PortugalLuzitin SA, S. Martinho do Bispo, Coimbra 3045-016, Portugal;;Chemistry Department, University of Coimbra, Coimbra 3004-535, PortugalFaculty of Chemistry, Jagiellonian University, Krakow 30-060, Poland;Bluepharma—Indústria Farmacêutica SA, S. Martinho do Bispo, Coimbra 3045-016, Portugal;

关键词: photodynamic therapy;    cancer treatment;    bacteriochlorin;    redaporfin;    intravenous formulation;    single-dose toxicity;    rodents;   

DOI  :  10.3390/ijms161226162

来源: mdpi

【 摘 要 】

We assessed the tolerability and safety in rodents of a single intravenous (i.v.) dose of redaporfin, a novel photosensitizer for Photodynamic Therapy (PDT) of cancer. Two approaches were used to evaluate acute toxicity: (i) a dose escalation study in BALB/c mice to evaluate the maximum tolerated dose of redaporfin; and (ii) a safety toxicology study in Wistar rats, of a single dose of redaporfin, with or without illumination, to evaluate possible signs of systemic toxicity. Redaporfin formulation was well tolerated by mice, with no signs of adverse reactions up to 75 mg/kg. In rats, there were no relevant changes, except for a significant, but transient, increase in the blood serum markers for hepatic function and muscle integrity, and also on neutrophil counts, observed after the application of light. The overall results showed that redaporfin-PDT is very well tolerated. No abnormalities were observed, including reactions at the injection site or skin phototoxicity, although the animals were maintained in normal indoor lighting. Redaporfin also showed a high efficacy in the treatment of male BALB/c mice with subcutaneously implanted colon (CT26) tumours. Vascular-PDT with 1.5 mg/kg redaporfin and a light dose of 74 J/cm² led to the complete tumour regression in 83% of the mice.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.